



an Open Access Journal by MDPI

Colorectal Adenocarcinoma: From Pathophysiology to Novel Therapeutic Approaches

Guest Editors:

Dr. Bong-hyeon Kye

Department of Surgery, St. Vincent's Hospital, The Catholic University of Korea, 93-1, Jungbu-daero, Paldal-gu, Suwon-si 16247, Gyeonggi-do, Korea

Dr. Ri Na Yoo

Division of Colorectal Surgery, Department of Surgery, St. Vincent Hospital, The Catholic University of Korea 93-6, Ji-dong, Paldal-gu, Suwon 442-723, Gyeonggi-do, Korea

Deadline for manuscript submissions:

closed (30 April 2023)

Message from the Guest Editors

Colorectal cancer (CRC) is the third most diagnosed cancer and a leading cause of cancer-related death worldwide. For the past several decades, significant progress in its molecular pathogenesis has led to precise treatment and patient management.

Knowledge regarding pathogenesis of colorectal cancer has grown, but it is still limited. Understanding the underlying molecular mechanisms of CRC is essential to improve early diagnosis and patient-tailored treatment. Furthermore, the unique clinicopathologic features and risk factors of CRC are not well defined yet. There is an urgent need to clarify clinical features and risk factors different from another GI tract malignancy to implement specific screening and management strategies. Especially, in this Special Issue, we would like to deal with the management of relatively rare conditions of CRC such as obstructive colon and rectal cancer, lateral pelvic lymph node metastasis from rectal cancer, early-onset (young age) CRC, and quality of life in CRC survivorships.

In this Special Issue, articles with a focus on the molecular biology, biomarkers, clinicopathologic characteristics, risk factors, and treatment strategies are invited.



mdpi.com/si/111041

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI